Matthew Sykes
Stock Analyst at Goldman Sachs
(4.01)
# 558
Out of 5,055 analysts
210
Total ratings
53.74%
Success rate
10.35%
Average return
Main Sectors:
Stocks Rated by Matthew Sykes
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| FTRE Fortrea Holdings | Maintains: Neutral | $7 → $5 | $10.40 | -51.92% | 4 | May 14, 2025 | |
| CTKB Cytek Biosciences | Maintains: Sell | $3.5 → $3 | $5.50 | -45.45% | 14 | May 12, 2025 | |
| TXG 10x Genomics | Maintains: Sell | $7.5 → $6.5 | $15.89 | -59.09% | 7 | May 12, 2025 | |
| BRKR Bruker | Maintains: Neutral | $50 → $45 | $41.62 | +8.12% | 5 | May 8, 2025 | |
| MYGN Myriad Genetics | Maintains: Buy | $14 → $8 | $6.72 | +19.14% | 12 | May 7, 2025 | |
| TWST Twist Bioscience | Maintains: Buy | $55 → $48 | $26.87 | +78.64% | 10 | May 6, 2025 | |
| SHC Sotera Health Company | Upgrades: Buy | $14 → $17 | $15.64 | +8.70% | 1 | May 5, 2025 | |
| ICLR ICON Public Limited Company | Maintains: Neutral | $180 → $160 | $162.29 | -1.41% | 4 | May 2, 2025 | |
| NEO NeoGenomics | Maintains: Buy | $15 → $10 | $10.34 | -3.29% | 8 | Apr 30, 2025 | |
| RVTY Revvity | Maintains: Buy | $140 → $125 | $92.73 | +34.80% | 2 | Apr 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $23 → $14 | $11.38 | +23.02% | 6 | Apr 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $260 → $240 | $221.21 | +8.49% | 5 | Apr 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $34 → $26 | $15.94 | +63.16% | 10 | Apr 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $190 → $170 | $167.81 | +1.31% | 4 | Mar 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $49 → $56 | $94.37 | -40.66% | 13 | Feb 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $70 → $80 | $128.06 | -37.53% | 11 | Feb 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $1.75 → $1.5 | $1.61 | -6.83% | 5 | Feb 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $160 → $190 | $204.28 | -6.99% | 13 | Jan 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $2.25 → $1.75 | $1.80 | -2.78% | 5 | Dec 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $7 → $4.25 | $3.64 | +16.76% | 10 | Dec 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $38 → $37 | $39.35 | -5.97% | 5 | Dec 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $75 → $65 | $67.03 | -3.03% | 13 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $280 → $250 | $220.61 | +13.32% | 2 | Nov 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $35 → $24 | $5.75 | +317.75% | 13 | Jul 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $1,150 → $1,300 | $1,403.08 | -7.35% | 7 | Jul 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $32 → $12 | $8.03 | +49.44% | 6 | Jul 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $550 → $640 | $578.71 | +10.59% | 6 | Apr 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $128 → $145 | $146.82 | -1.24% | 4 | Dec 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $44.32 | - | 5 | Dec 7, 2023 |
Fortrea Holdings
May 14, 2025
Maintains: Neutral
Price Target: $7 → $5
Current: $10.40
Upside: -51.92%
Cytek Biosciences
May 12, 2025
Maintains: Sell
Price Target: $3.5 → $3
Current: $5.50
Upside: -45.45%
10x Genomics
May 12, 2025
Maintains: Sell
Price Target: $7.5 → $6.5
Current: $15.89
Upside: -59.09%
Bruker
May 8, 2025
Maintains: Neutral
Price Target: $50 → $45
Current: $41.62
Upside: +8.12%
Myriad Genetics
May 7, 2025
Maintains: Buy
Price Target: $14 → $8
Current: $6.72
Upside: +19.14%
Twist Bioscience
May 6, 2025
Maintains: Buy
Price Target: $55 → $48
Current: $26.87
Upside: +78.64%
Sotera Health Company
May 5, 2025
Upgrades: Buy
Price Target: $14 → $17
Current: $15.64
Upside: +8.70%
ICON Public Limited Company
May 2, 2025
Maintains: Neutral
Price Target: $180 → $160
Current: $162.29
Upside: -1.41%
NeoGenomics
Apr 30, 2025
Maintains: Buy
Price Target: $15 → $10
Current: $10.34
Upside: -3.29%
Revvity
Apr 29, 2025
Maintains: Buy
Price Target: $140 → $125
Current: $92.73
Upside: +34.80%
Apr 29, 2025
Downgrades: Neutral
Price Target: $23 → $14
Current: $11.38
Upside: +23.02%
Apr 23, 2025
Maintains: Buy
Price Target: $260 → $240
Current: $221.21
Upside: +8.49%
Apr 17, 2025
Maintains: Buy
Price Target: $34 → $26
Current: $15.94
Upside: +63.16%
Mar 21, 2025
Downgrades: Neutral
Price Target: $190 → $170
Current: $167.81
Upside: +1.31%
Feb 21, 2025
Maintains: Buy
Price Target: $49 → $56
Current: $94.37
Upside: -40.66%
Feb 19, 2025
Maintains: Neutral
Price Target: $70 → $80
Current: $128.06
Upside: -37.53%
Feb 18, 2025
Maintains: Neutral
Price Target: $1.75 → $1.5
Current: $1.61
Upside: -6.83%
Jan 28, 2025
Maintains: Buy
Price Target: $160 → $190
Current: $204.28
Upside: -6.99%
Dec 5, 2024
Downgrades: Sell
Price Target: $2.25 → $1.75
Current: $1.80
Upside: -2.78%
Dec 5, 2024
Downgrades: Sell
Price Target: $7 → $4.25
Current: $3.64
Upside: +16.76%
Dec 5, 2024
Downgrades: Neutral
Price Target: $38 → $37
Current: $39.35
Upside: -5.97%
Nov 6, 2024
Maintains: Buy
Price Target: $75 → $65
Current: $67.03
Upside: -3.03%
Nov 1, 2024
Maintains: Buy
Price Target: $280 → $250
Current: $220.61
Upside: +13.32%
Jul 9, 2024
Maintains: Buy
Price Target: $35 → $24
Current: $5.75
Upside: +317.75%
Jul 9, 2024
Maintains: Neutral
Price Target: $1,150 → $1,300
Current: $1,403.08
Upside: -7.35%
Jul 9, 2024
Maintains: Sell
Price Target: $32 → $12
Current: $8.03
Upside: +49.44%
Apr 10, 2024
Maintains: Buy
Price Target: $550 → $640
Current: $578.71
Upside: +10.59%
Dec 7, 2023
Maintains: Buy
Price Target: $128 → $145
Current: $146.82
Upside: -1.24%
Dec 7, 2023
Upgrades: Buy
Price Target: n/a
Current: $44.32
Upside: -